	Tender Reference no.-BMSIC/DRUG/17-06	
S.N.	***Technical Eligibility Criteria as per NIT***	***Firm Name - M/s Bharat Biotech International Limited*** ***Corporate Address:- Bharat Biotech International Limited , Genome valley, Turkapally, Shameerpet Mandal, Hyderabad - 500078, Telangana state.*** ***Manufacture Unit Address:- Genome valley, Turkapally, Shameerpet Mandal, Ranga Reddy District - 500078.***
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	Scanned copy of Memorandum of Association of M/s Bharat Biotech International Limited is submitted (Pg. no. 112-118) Scanned copy of Articles of Association of M/s Bharat Biotech International Limited is submitted (Pg. no. 47-111) Scanned copy of Certificate of Incorporation (No. 01-23232 of 1995-96 dated 15.02.1996) of M/s Bharat Biotech International Limited is submitted. (Pg. no. 120) Scanned copy of Bidder Information/ Bidder details is submitted as per annexure V of NIT. (Pg. no. 164) **Note:-(i) Name and Desiganation of Authorized signatory is not mentioned at sl no. 7 of Annexure-V. Name of the Bidder with Address is mentioned in that column.** **(ii) At Sr no. 6 Name of proprietor (For Limited Company) is mentioned as Dr. Krishna Murthy Ella, Chairman cum Managing Director with Comapny Address.**
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	(a) Scanned Copy of Certified true Copy of the resolution of Board of Director held on 06.01.2015 is submitted wherein it is state that Mr. T Srinivas be and is hereby appointed as the Chief Financial Officer of the Company with effect from 06.01.2015 for 5 years (Pg. no. 40) (b) Scanned Copy of Certified true Copy of the resolution of Board of Director held on 27.03.2014 is submitted wherein it is state that Mr. Tadepally Srinivas Vice President, Finance be and is hereby authorized to (a) appear, sign, verify..... etc in Connection with any suit or proceeding. (pg no. 39) (c) Scanned Copy of General Power of Attorney given by Dr. V. Krishna Mohan whole time Director of the firm is submitted wherein it is state that the Company hereby Consititute in appoint Mr. T. srinivas Chief Financial Officer as Power of Attorney holder to quote, Finalize and Sign all Document and do all lawfull Acts. on behalf of the Company pertaining to the tender issued by Govt. and its agencies. (pg. no. 41 & 42) **Note:- In context to delegate power of attorney by Dr. V. Krishna Mohan, whole time Director to Mr. T Srinivas, such Resolution of Board is not submitted by the bidder.**
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	Scanned copy of List of Items quoted is submitted as per annexure III of NIT. (Total No. of items quoted- 02) (pg. no. 122) Nit sl. No. Name of the Drugs specification/ Strength Pack Size Dosage form 1 Rabies Vaccine, Human IP (Cell Culture) (Lyophilised) 2.5IU 1ml vial Intramascular/ Intradermal 2 Rabies Vaccine, Human IP (Cell Culture) (Lyophilised) 2.5IU 0.5 ml vial Intramascular/ Intradermal

105

4	• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). • In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation. • Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organization). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed.The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall apply. • For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect. • FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable. Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)	(a) Scanned Copy of Certificate of renewal in form 26 H issued on 27.04.2013 by Joint Director DCA Govt. of A.P. Hyderabad is submitted wherein it is state that Licence no. 03/HD/AP/98/V/R granted on 14.10.1998 has been renewed from 01.01.2012 to 31.12.2016. (pg. no. 21 & 22) (b) Scanned Copy of Licence validity Certificate (L. Dis. No. 12310/E(M)/TS/2016 dated 06.01.2017) issued by Joint Director and Licensing Authority DCA Govt. of Telangana is submitted wherein it is stated that their application for renewal for the year 01.01.2017 to 31.12.2021 was received and is under process. the Licence in form 28 D shall Continue to be in force as per Rule 74 of Drugs & Cosmetics Act., 1940 and Rules made thereunder till grant of renewal. (Pg. no. 24) **Note:-(i) Manufacturing Licence in form 28 H is not submitted.** **(ii) The quoted product is not highlighted by the bidder in submitted approved product list as per clause 3 (f) of NIT** **(iii)Approval for the quoted product, Rabies Vaccine Human I.P. is not submitted. However, approval for the product Rabies Vaccine I.P. is submitted.** (c) Product at NIT sl. no. 1 [Rabies Vaccine, Human IP (Cell Culture) (Lyophilised), 2.5IU, 1.0 ml vial] is mentioned at sl. no. 19 as **Rabies Vaccine I.P. Purified, Inactivated, Lyophilized Rabies Vaccine, prepared on Vero Cells** in submitted approved product list. (Pg. no. -15) (d) Product at NIT sl. no. 2 [Rabies Vaccine, Human IP (Cell Culture) (Lyophilised), 2.5IU, 0.5 ml vial] is mentioned at sl. no. 15 & 1 as **Rabies Vaccine I.P. Purified, Inactivated, Lyophilized Rabies Vaccine, prepared on Vero Cells** in submitted approved product list. (Pg. no. -16 & 1) (e) Scanned Copy of Market Standing Certificate (L. Dis No. 10550/E(M)/TS/2017 dated 06.09.2017) issued by licensing and Controlling Authority DCA Govt. of Telangana, Hyderabad is submitted wherein it is state that they are manufacturing and Marketing the Following Products last three years (Pg no. 45 & 46)
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	N/A
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	N/A
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Scanned Copy of Non Conviction Certificate (L. Dis. No. 7887/E(M)/TS/2017 dated .....06.2017) issued by Joint Director and Licensing Authority, DCA, Govt. of Telangana is submitted wherein it is stated that the Manufacturer has not been convicted and the product quoted have not been cancelled during the last three years Viz 2014-15, 2015-16 and 2016-17 (Pg. no. 44)

S.N. (1 to 6) 31/10/17

104

8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	(a) Scanned Copy of GMP Certifiacte of (L. Dis. No. 12041/E(M)/TS/2016 dated 09.12.2016) Licensing and Controlling Authority DCA, Govt. of Telangana is submitted wherein it is stated that the firm is following Good Manufacturing Practices as Stipulated under the provision of revised schedule "M" of Drugs and Cosmetics Rules, 1945. (Pg. no. 133 to 142) (b) Scanned Copy of WHO-GMP Certificate for the products mentioned for the purpose of participation in tender of Rajasthan and Haryana is also submitted (Pg. no. 128 to 132)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section.In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production (Importing)capacity shall be adequate for requirement laid in NIT. Importers will have also to submit Invoices/Evidence of import in items of said product with quantity details. As per Clause 3(k).	Scanned Copy of Production Capacity Certificate (L.Dis No. 9995/M3B/2010 dated 25.08.2010) issued by Deputy Director, DCA Govt. of Andhra Pradesh is submitted wherein it is stated that annual Capacity in units is 60,00,000 for the items Indirab (Purified, Inactivated, Lyophilized Rabies Vaccine, prepared on Vero Cells) (Pg. no. 38)
10	An affidavit (with stamp)sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Scanned copy of notarised affidavit for non blacklisting is submitted as per annexure II of NIT (Pg. no. 150)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b) .	BG NO -0192117BG0000633 Date of Issue 29-09-2017 `1,00,000/- Valid Upto 30-06-2018 Page-147
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	DD No -"055302" ` 10,000/- CITI Bank Date Of Issue 03-10-2017 Page No 36
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	FY -2016-17 `5,15,54,94,291/- Page No 158 FY -2015-16 `4123063137/- Page No -155 FY-2014-15`3047598735/- Page No-152
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	AY 2016-17 Page No -126 AY 2015-16 Page No -125 AY 2014-15 Page No -124
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	PAN No :- "AABCB3822B" Page No 43
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	GSTIN - "36AABCB3822B1ZB" Page No -128
17	Affidavit (with stamp)declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Scanned copy notarised affidavit regarding acceptance of tender conditions is submitted as per annexure IV of NIT (pg. no. 149)

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due deligence and care, on the basis of document provided by BMSICL. Inspite, some inadvertent dicrepencies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepencies is observed, for rectification.